Avicanna Reports Positive Adjusted EBITDA for Q3 2026 and Provides Corporate Update

Avicanna Reports Positive Q3 2026 Results

Adjusted EBITDA of $0.22 million, improves $1.01 million year-over-year, operating loss narrows by 80%Proprietary products reach 31% of MyMedi.ca sales, up from 19%; QUIX™ launches with 10 SKUs

Format

PNG

Source

Avicanna Inc.

Téléchargements